About Us
Experts in designing medicines to improve patient care
At our core, we are experts in designing, developing, and bringing new medicines to patients
Our commitment extends from the initial stages of development through regulatory approval and beyond. We excel in innovating new formulations and exploring alternative delivery methods for existing medications.
Our in-house pharmaceutical development programmes are significantly de-risked compared to traditional biotech and pharma models. We create specially designed medicines to maximise efficacy and ease of use, thereby improving patient care and disease management.
Our most recent innovation is a novel intranasal dry powder delivery device (DriDose®), combined with our bespoke formulation development expertise. The DriDose® technology aims to ease drug administration for patients and healthcare professionals. We have developed single-use and reusable versions of the device to cater to the requirements of different candidates.
Among our other successes, we have developed and obtained marketing authorisations for three paediatric products, with Jylamvo®, our oral methotrexate solution, also licensed for adults in the US.
We are open to co-development opportunities where partners can utilise our intranasal formulation expertise and DriDose® devices, working together in pursuit of better healthcare solutions for patients.
To discuss collaboration opportunities:
-
The Directors of Therakind believe that a sound governance structure ensures the Company has appropriate decision-making processes and controls in place to balance the interests of all stakeholders, including shareholders, employees, suppliers, business partners, patients and the community.
-
The Company has a culture of open communication, transparency, diversity, teamwork, accountability and innovation. The Company actively engages its employees through communication of Company news and information in a variety of formats. Management encourages feedback from all employees and engages in dialogue across all levels of the business and has a policy of accessibility of senior management to all staff.
The Company aims to drive sustainability through its own operations and its choice of suppliers. The Company is committed to the principles of conservation of reduce, reuse, and recycle. The Company supports its local communities by maintaining sound business practices and by acting as a good corporate citizen, a valued employer and a responsible member of its local business community.
-
The Board has responsibility for the oversight of the Company’s operations ensuring:
Competent and prudent planning and management.
Adequate system of internal control and accurate accounting records.
Compliance with statutory and regulatory obligations.
The Board regularly reviews key areas of business risk including commercial, financial, intellectual property, regulatory compliance, research and development, staff, and key partners. Such review includes an assessment of the potential impact and if necessary, appropriate mitigation strategies and actions.